This phase II trial is assessing how effective a new intravenous therapy (INCMGA00012) is in treating patients with squamous carcinoma of the anal canal (SCAC) who have gotten worse after chemotherapy.
This trial is treating patients with squamous carcinoma of the anal canal (SCAC) .
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy
Commercial Sponsor
Incyte Corporation
Summary
Eligible participants with locally advanced or metastatic squamous carcinoma of the anal canal, who have progressed following chemotherapy, will receive intravenous INCMGA00012 at a recommended phase II dose once every 28 days.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More